The next main battleground in the development of anti-obesity drugs

NovoNordisk and Eli Lilly clash in hibernation research as they vie for the mega-blockbuster desperate anti-obesity drug market. Spring awakening to rapidly explore molecular switches in metabolism and weight regain, aiming for a fifth generation of new drugs.
https://miyata-bio.net/column/0000308/